Ongoing proof-of-concept trial AdrenOSS-II testing Adrecizumab in early septic shock Adrecizumab is a first-in-class antibody targeting Adrenomedullin, to rescue vascular function Vascular integrity, regulated by Adrenomedullin, is key to preventing vascular leakage and septic shock
For the second time, Adrenomed and sphingotec host international scientific symposium on vascular integrity in Berlin Top-tier clinical scientists and key opinion leaders discuss potential of Adrenomedullin in diagnosis and treatment of acute heart failure
Adrenomed AG, the vascular integrity company, today announced the closing of a EUR 24 million series D financing round co-led by Wellington Partners and HBM Healthcare Investments as new investors.
Three scientific papers report how the monoclonal therapeutic antibody Adrecizumab reverses vascular hyperpermeability in sepsis. Adrecizumab acts through stabilization of the vasoactive peptide hormone adrenomedullin and its redistribution from tissue into blood plasma without blocking
First patient enrolled in Phase II study ADR-02 (AdrenOSS-2), designed to demonstrate safety and efficacy of Adrecizumab in patients with early septic shock Study to be conducted in Germany, the Netherlands, Belgium, and France Population
Comprehensive clinical safety review of Adrecizumab to be presented Opinion leaders will discuss effects of Adrecizumab and its target Adrenomedullin on septic shock mortality in four sessions Adrenomed expects to start enrolment for Phase II
Germany first country to grant full approval for Phase II study ADR-02 (AdrenOSS-2) with Adrecizumab in patients with early septic ADR-02 study to enroll 300 patients in Germany, Belgium, France and the Netherlands for proof
Phase-I study demonstrates excellent tolerability and safety of Adrecizumab in healthy subjects Unique mode of action confirmed in humans Phase-II study in septic shock is on the way Adrenomed plans additional Phase-II study in acute